NASDAQ$AXSM
Axsome Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Axsome reported first quarter results, marked by Auvelity's first full quarter of launch and revenue from Sunosi license agreement.
Axsome Therapeutics reported a total revenue of $94.6 million for Q1 2023, driven by net product sales of $28.6 million and license revenue of $65.7 million. Auvelity net product sales were $15.7 million, and Sunosi net product sales were $12.9 million. The company's net loss for the quarter was $11.2 million, or $(0.26) per share.
- Total revenue for the first quarter of 2023 was $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and royalty revenue of $0.3 million.
- Auvelity net product sales were $15.7 million for the first quarter of 2023.
- Sunosi net product sales were $12.9 million for the first quarter of 2023, including $1.7 million in international net sales booked by Axsome.
- Net loss for the first quarter of 2023 was $11.2 million or $(0.26) per share.
Headline financials
Revenue & EPS history
Axsome · Revenue · Quarterly
$94.6M
Revenue by segment
Axsome · $28.6M total across 2 segments · Q1 2023
- AUVELITY$15.7M—54.9%
- SUNOSI$12.9M—45.1%
Forward guidance
Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-1.0%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+1.7%
Avg return
30 days after
51%
21 / 41 earnings
Positive
+12.9%
Q1 2022
Best reaction
-53.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.1% | +5.3% | +13.0% | |
| Q4 2025 | -4.7% | -10.8% | -11.9% | |
| Q3 2025 | +1.9% | +2.3% | +9.5% | |
| Q1 2025 | +3.7% | -4.0% | -3.6% | |
| Q4 2024 | -2.3% | +5.0% | -3.7% | |
| Q3 2024 | +7.5% | +2.4% | +3.7% | |
| Q2 2024 | +1.3% | -1.6% | +13.2% | |
| Q1 2024 | +2.9% | -3.1% | -0.9% | |
| Q4 2023 | -11.5% | -14.9% | -12.9% | |
| Q3 2023 | -3.1% | -11.9% | +6.5% | |
| Q2 2023 | -1.5% | -5.5% | +10.7% | |
| Q1 2023 | +4.1% | +7.1% | +2.4% | |
| Q4 2022 | +11.7% | +6.9% | +2.3% | |
| Q3 2022 | +11.2% | +3.4% | +36.9% | |
| Q2 2022 | +11.7% | +6.8% | +41.3% | |
| Q1 2022 | +12.9% | -6.1% | -24.3% | |
| Q4 2021 | +11.9% | +6.4% | +47.2% | |
| Q3 2021 | +1.4% | -2.3% | -12.6% | |
| Q2 2021 | -53.5% | -55.3% | -48.9% | |
| Q1 2021 | +0.1% | +2.6% | +11.5% | |
| Q4 2020 | +3.6% | -3.5% | -15.9% | |
| Q3 2020 | -9.7% | -6.3% | +7.1% | |
| Q2 2020 | -0.6% | +1.2% | -7.3% | |
| Q1 2020 | -2.8% | -7.9% | -15.7% | |
| Q4 2019 | -16.8% | -38.7% | -23.8% | |
| Q3 2019 | -1.2% | -4.6% | +76.4% | |
| Q2 2019 | +2.2% | +11.0% | -0.5% | |
| Q1 2019 | +7.2% | +10.7% | +12.2% | |
| Q4 2018 | +4.6% | +24.3% | +29.2% | |
| Q3 2018 | -15.8% | -28.1% | -24.7% | |
| Q2 2018 | -1.9% | -8.6% | +27.6% | |
| Q1 2018 | +1.5% | +3.0% | +4.5% | |
| Q4 2017 | +2.6% | +6.5% | -8.4% | |
| Q3 2017 | -4.1% | +1.0% | -0.5% | |
| Q2 2017 | -5.0% | -12.6% | -19.3% | |
| Q1 2017 | -1.2% | -1.2% | -4.8% | |
| Q4 2016 | -4.1% | +6.1% | -27.6% | |
| Q3 2016 | +0.7% | +4.1% | -17.8% | |
| Q2 2016 | -1.4% | -3.4% | -1.6% | |
| Q1 2016 | -1.4% | -3.4% | -1.6% | |
| Q4 2015 | -10.0% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro